Fulgent Genetics, Inc. (FLGT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US3596641098
Fulgent Genetics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 322.67 m USD |
| Gross profit | 130.88 m USD |
| Operating income | -91.10 m USD |
| EBIT | -100.87 m USD |
| Net income | -60.51 m USD |
| Diluted EPS – continuing operations | -1.97 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
More stocks
- Shentong Technology Group Co Ltd (605228.SS)
- EcoRodovias Infraestrutura e Logística S.A (ECOR3.SA)
- Henan Carve Electronics Technology Co. Ltd. (301182.SZ)
- Shenyang Blue Silver Ind Auto (300293.SZ)
- Atal SA (1AT.WA)
- Wave Life Sciences, Inc. (WVE)
- Smartone Telecommunications Holdings Ltd (315.HK)
- Jiangsu SINOJIT Wind Energy Technology Co Ltd (601218.SS)
- Critical Metals Corp (CRML)
- Shandong Keyuan Pharmaceutical Co. Ltd. A (301281.SZ)
- Melco International Development Ltd (200.HK)
- Newonder Special Electric Co.Ltd (301120.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.